-
New results on the Chinese vaccine
Importantly, this was the first study of an inactivated SARS-CoV-2 vaccine to include participants older than 60 years—the most vulnerable age group for this infection. In the phase 1 dose-escalating trial, the vaccine was given at a two-dose schedule at three different concentrations (2 μg, 4 μg, and 8 μg per dose) and was well tolerated in both […] The post New results on the Chinese vaccine appeared first on Marginal REVOLUTION.
More like this (3)
-
The First Dose is Good
WSJ: The Covid-19 vaccine developed by Pfizer Inc. and BioNTech SE generates robust immunity after one...
-
Vaccinations begin at the nursing home where 46 died in the pandemic’s first days.
Continue reading the main storyA nurse at the suburban Seattle nursing home that was ravaged by...
-
Interim analysis shows 91.4% efficacy for the Russian Sputnik vaccine
The efficacy of the Sputnik V vaccine is 91.4%, based on the second interim analysis of...
